What is IGC's current stock price?

IGC (IGC Pharma, Inc.) is currently trading at $0.28 with a market cap of $28.0M.

What sector is IGC Pharma, Inc. in?

IGC Pharma, Inc. (IGC) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

Back to Market返回行情

IGC IGC Pharma, Inc.

AMEXHealthcare

$0.2799-1.75%ClosedMarket Cap: $28.0M

As of 2026-10-09 16:00

Why IGC matters now

IGC Pharma, Inc. (IGC) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.28 with -1.75% on the session and $28.0M in market capitalization.

The latest indexable market news headline is "IGC Pharma, Inc. (NYSEAMERICAN:IGC) Stock Short Interest Jumps 48.0%" from Defense World.

Latest News

IGC Pharma, Inc. (NYSEAMERICAN:IGC) Stock Short Interest Jumps 48.0%Defense World · 2026-10-03

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026Accesswire · 2026-09-28

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment ClosureAccesswire · 2026-08-17

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline ReadoutAccesswire · 2026-08-11

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short CampaignAccesswire · 2026-07-29

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

AMEX

Beta

0.48

IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.